OTC Markets OTCPK - Delayed Quote USD

Shanrong Biotechnology Corp. (SRBT)

0.4680
0.0000
(0.00%)
At close: May 20 at 4:00:00 PM EDT
Loading Chart for SRBT
  • Previous Close 0.0000
  • Open 0.3500
  • Bid 0.2800 x 40000
  • Ask 0.5000 x 40000
  • Day's Range 0.3500 - 0.4705
  • 52 Week Range 0.0940 - 3.8300
  • Volume 5,000
  • Avg. Volume 545
  • Market Cap (intraday) 468.225M
  • Beta (5Y Monthly) -0.61
  • PE Ratio (TTM) --
  • EPS (TTM) -3.7400
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Shanrong Biotechnology Corp. operates as a project management and executive consulting company. The company refurbishes and upgrades armored vehicles with digital communications, as well as provides spare parts and equipment for military and police forces; and offers onsite maintenance, maintenance training, operator training, and tactical training services. It also conducts program management, business development, and strategic studies and analyses in the defense, homeland security, information technology, and telecommunications markets. The company was formerly known as Defense Solutions Holding, Inc. and changed its name to Shanrong Biotechnology Corp. in September 2017. Shanrong Biotechnology Corp. is based in Beverly Hills, California.

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SRBT

View More

Performance Overview: SRBT

Trailing total returns as of 5/20/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SRBT
387.50%
S&P 500 (^GSPC)
1.00%

1-Year Return

SRBT
26.49%
S&P 500 (^GSPC)
11.91%

3-Year Return

SRBT
48.00%
S&P 500 (^GSPC)
52.27%

5-Year Return

SRBT
65.96%
S&P 500 (^GSPC)
99.91%

Compare To: SRBT

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SRBT

View More

Valuation Measures

Annual
As of 5/20/2025
  • Market Cap

    468.23M

  • Enterprise Value

    468.23M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -2.07k

  • Diluted EPS (ttm)

    -3.7400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    30.87k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: SRBT

View More

Company Insights: SRBT

Research Reports: SRBT

View More

People Also Watch